Nexium耐信品牌怎么样申请店铺

我要投票

Nexium耐信在医疗器械行业中的票数：621 更新时间：2026-01-26

Nexium耐信是哪个国家的品牌？「Nexium耐信」是阿斯利康投资(中国)有限公司旗下著名品牌。该品牌发源于英国，在1999年期间创立，经过多年的不懈努力和高速发展，现已成为行业的标杆品牌。

外推网助力Nexium耐信品牌出海！将品牌入驻外推网，定制Nexium耐信品牌推广信息，可以显著提高Nexium耐信产品曝光，简直是跨境电商爆单神器！目前仅需1000元/年哦~

一般指埃索美拉唑镁肠溶片，适用于抑制胃酸分泌，药片应和液体一起整片吞服，而不应当咀嚼或压碎

耐信一般指埃索美拉唑镁肠溶片，适用于胃食管反流性疾病(GERD)－糜烂性反流性食管炎的治疗－已经康复的食管炎患者防止复发的维持治疗－胃食管反流性疾病(GERD)的症状控制与适当的抗菌疗法联合用药去除幽门螺杆菌，并且－愈合与幽门螺杆菌感染相关的十二指肠溃疡－防止与幽门螺杆菌相关的消化性溃疡复发。

禁忌

已知对埃索美拉唑、其它苯并咪唑类化合物或本品的任何其他成份过敏者禁用。

注意事项

1.当出现任何报警症状(如显著的非有意识的体重减轻、反复呕吐、吞咽困难、呕血或黑便)，怀疑有胃溃疡或已患有胃溃疡时，应排除恶性肿瘤，因为使用埃索美拉唑镁肠溶片治疗可减轻症状，延误诊断。

2.使用该药治疗的患者(特别是使用1年以上者)应定期进行监测。

3.应告知按需治疗的患者，在其症状特征改变时与医生联系。在按需用药治疗时，应考虑由于埃索美拉唑血药浓度的波动而可能产生的药物相互作用（见【药物相互作用】）。

4.当埃索美拉唑用于去除幽门螺杆菌的治疗时，应考虑三联疗法中所有成份的可能的药物相互作用。克拉霉素是CYP 3A4的有效抑制剂，因此当三联疗法的患者同时服用其它也经CYP 3A4代谢的药物，如西沙必利时，应考虑克拉霉素的禁忌和相互作用。

5.伴有罕见的遗传性疾病，如果糖耐受不良，葡萄糖-半乳糖吸收障碍或蔗糖酶-异麦芽糖酶不足的患者，不可服用本品。

6.肾功能损害：肾功能损害的患者无需调整剂量。对于严重肾功能不全的患者，由于使用该药的经验有限，治疗时应慎重(见【药代动力学】)。

7.肝功能损害轻到中度肝功能损害的患者无需调整剂量。对于严重肝功能损害的患者，埃索美拉唑镁肠溶片的剂量不应超过20 mg(见【药代动力学】)。

8.对驾驶和使用机器能力的影响尚未观察到这方面的影响。

Generally, it refers to esomeprazole enteric coated tablets, which are suitable for inhibiting the secretion of gastric acid. The tablets should be swallowed together with the liquid, and should not be chewed or crushed. Nexium generally refers to esomeprazole enteric coated tablets, which are suitable for the treatment of gastroesophageal reflux disease (GERD) - erosive reflux esophagitis - the maintenance treatment to prevent recurrence of recovered esophagitis patients - gastroesophageal reflux disease (GER D) Symptom control combined with appropriate antimicrobial therapy for Helicobacter pylori eradication and - healing of duodenal ulcer associated with Helicobacter pylori infection - prevention of recurrence of peptic ulcer associated with Helicobacter pylori. It is forbidden to use esomeprazole, other benzimidazoles or any other ingredients of the product if it is known to be allergic. Note 1. In case of any alarm symptoms (such as significant unconscious weight loss, repeated vomiting, dysphagia, hematemesis or black stool), suspected gastric ulcer or gastric ulcer, malignant tumor should be excluded, because the use of esomeprazole enteric coated tablets can reduce symptoms and delay diagnosis. 2. Patients treated with the drug (especially those who have used it for more than 1 year) should be monitored regularly. 3. Patients who need to be treated should be informed to contact doctors when their symptoms and characteristics change. In the treatment of on-demand medication, the possible drug interactions due to the fluctuation of esomeprazole blood concentration should be considered (see drug interactions). 4. When esomeprazole is used to remove Helicobacter pylori, the possible drug interactions of all components in triple therapy should be considered. Clarithromycin is an effective inhibitor of CYP3A4. Therefore, when patients take other drugs metabolized by CYP3A4, such as cisapride, the taboo and interaction of clarithromycin should be considered. 5. Patients with rare genetic diseases, such as poor glucose tolerance, glucose galactose absorption disorder or sucrase isomaltase deficiency, should not take this product. 6. Renal function damage: Patients with renal function damage do not need to adjust the dose. For patients with severe renal insufficiency, due to the limited experience of using the drug, the treatment should be cautious (see [pharmacokinetics]). 7. There is no need to adjust the dosage in patients with mild to moderate liver function damage. The dose of esomeprazole enteric coated tablets should not exceed 20 mg in patients with severe liver function damage (see [pharmacokinetics]). 8. The impact on the ability to drive and use the machine has not been observed.

本文链接： https://brand.waitui.com/c602252ec.html 联系电话：请联系客服添加联系邮箱：请联系客服添加